• Explore /
  • Poster
  • / First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

Abstract Poster

Authors

null

Muhammad Ali Khan

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ

Muhammad Ali Khan , Syed Arsalan Ahmed Naqvi , Manal Imran , Aneeta Channar , Akshat Saxena , Ammad Raina , Kaneez Zahra Rubab Khakwani , Zaryab Bin Riaz , Adam McLain Kase , Mitchell R. Humphreys , Cassandra N. Moore , Jacob Orme , Daniel S Childs , Parminder Singh , Alan Haruo Bryce , Jeanne M. Palmer , Irbaz Bin Riaz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 173)

DOI

10.1200/JCO.2024.42.4_suppl.173

Abstract #

173

Poster Bd #

H2

Abstract Disclosures

Similar Posters

First Author: Xuanjun Guo

First Author: Syed Arsalan Ahmed Naqvi

First Author: Elena Castro

First Author: Ruben Raychaudhuri